PQT
The Setup
PQT Health
Issue live · 2026-10-14
Week of October 12, 2026 · Healthcare Weekly Brief
Humana's Star Surge, UnitedHealth's Raise and a Hot CPI Rotation
Star Ratings crowned a new Medicare Advantage winner, UnitedHealth raised guidance for the third time and investors fled into healthcare as inflation hit 3.7%, while hospitals and ACA enrollees face a costlier 2027.
01
The Setup
The forces shaping this week's market
2027 Star Ratings made Humana the top Medicare Advantage beneficiary as UnitedHealth beat Q3 and raised 2026 guidance to at least $20.50. A hot September CPI (3.7%) pushed the 10-year to about 5.28% yet health care led the S&P 500 on Oct 14 as investors rotated out of tech. Hospitals sued again over the 340B rebate pilot, Stryker bought into CMR Surgical, and 2027 ACA premiums are set to rise about 15% at the median.
01
Humana Wins the Stars Reset
95% of Humana's MA members land in 4+ star plans for 2027, up from 20%. HUM jumped 11.6% Oct 9; UNH and CVS likely lose 4+ star share.
02
UnitedHealth Raises, Trend Stays Hot
Q3 adj EPS $4.69, guidance at least $20.50. But a $610M reserve release helped, and commercial trend is still above 11%.
03
Hot CPI, Healthcare Hides
CPI hit 3.7% and the 10-year rose to ~5.28%, yet health care led the S&P 500 up 2.44% as money left tech. Biotech stayed flat.
02
Scorecard
Who wins, who is squeezed
▲ Winner
Humana, UnitedHealth and big pharma
- Humana rose 11.6% Oct 9 after its 4+ star share jumped to 95%.
- UnitedHealth beat, raised and gained 4.8% Oct 14.
- Lilly and Merck each rose 3.8% in the Oct 14 rotation.
$HUM
$UNH
$LLY
▼ Squeezed
Safety-net hospitals, ACA buyers, Neurocrine
- 340B rebates would make hospitals front drug costs from January.
- ACA buyers face a 15% median proposed hike after 20% in 2026.
- Neurocrine fell 4.4% Oct 13 on Vykat XR safety concerns.
$NBIX
$XBI
◆ Mixed
Surgical robotics
- Stryker took a $400M CMR stake with a buyout option.
- J.P. Morgan sees little near-term hit to Intuitive.
- Intuitive reports Q3 Oct 20 after the close.
$SYK
$ISRG
03
The Numbers
Figures that matter this week
04
Where Prices Sit
Benchmark levels in their 52-week range
Last available snapshots as of 2026-10-14. The marker shows the current price within the 52-week range.
$173.93
$141.05 low
92.5% of range
$176.60 high
Up 2.5% Oct 14 and 3.0% since Oct 7. Health care led the S&P 500 on a hot CPI day; now 1.5% below its Aug 19 high.
$146.76
$103.43 low
65.2% of range
$169.89 high
Flat Oct 14 and down 2.3% since Oct 7. Small-cap biotech did not join the defensive bid with the 10-year near 5.28%.
$395.76
$255.97 low
68.0% of range
$461.62 high
Up 4.8% Oct 14 and 5.3% since Oct 7 after a Q3 beat and a raise to at least $20.50 adjusted EPS.
05
Equity Watch
Names in focus this week
Filter
Sort
| Ticker | Company | Sector | Direction | Key Catalyst |
|---|---|---|---|---|
UNH$395.76 |
UnitedHealth Group | Payers/Managed Care | ▲ Bullish, post-beat |
Q3 beat and third 2026 guidance raise; AEP opens Oct 15; full 2027 outlook before year-end+ WHY IT MATTERS |
HUM$427.20 |
Humana | Payers/Managed Care | ▲ Bullish, Stars windfall |
95% of MA members in 4+ star plans for 2027 vs 20%; AEP enrollment mix+ WHY IT MATTERS |
LLY$1,210.79 |
Eli Lilly | Pharma | ▲ Bullish, defensive bid |
Rotation into large-cap pharma; 10-year near 5.28%; Q3 earnings later this month+ WHY IT MATTERS |
MRK$147.35 |
Merck | Pharma | ▲ Rebounding |
Defensive rotation; I-DXd BLA withdrawn (Oct 10 PDUFA no longer pending); Capvaxive competition+ WHY IT MATTERS |
NBIX$135.92 |
Neurocrine Biosciences | Biotech/Specialty Pharma | ▼ Pressured |
Renewed Vykat XR safety scrutiny (STAT, Oct 13); FDA postmarketing review+ WHY IT MATTERS |
SYK$281.63 |
Stryker | MedTech | ◆ Mixed, deal digestion |
$400M CMR Surgical stake with exclusive buyout option; US Versius distribution+ WHY IT MATTERS |
ISRG$420.22 |
Intuitive Surgical | MedTech | ◆ Binary catalyst |
Q3 earnings Oct 20 after close (consensus EPS $2.54); Stryker/CMR competitive entry+ WHY IT MATTERS |
06
One-Week Scenarios
One-week outlook: October 14 - October 21, 2026
Probabilities are analytical judgments. Price ranges are illustrative, not forecasts. Hover a band to isolate its case.
BASE 55%BULL 20%BEAR 25%55%
Base caseRotation holds, earnings in line
AEP opens quietly, Intuitive and Elevance report roughly in line, and Fed-hike chatter keeps the 10-year between 5.2% and 5.35%. XLV consolidates just below its August high, XBI stays range-bound, UNH holds most of its post-earnings gain.
XLV $170-$177
XBI $142-$151
UNH $382-$405
20%
Bull caseBreakout on benign trend
Elevance and Molina describe moderating Medicaid and ACA trend, Intuitive beats on procedures, and yields ease. XLV breaks to a new 52-week high and biotech joins.
XLV $176-$181
XBI $150-$157
UNH $403-$420
25%
Bear caseRotation reverses, trend bites
Elevance flags hot commercial or ACA trend, Fed-hike odds climb and tech rebounds, pulling money back out of defensives. Payers give back the week's gains and cash-burning biotech falls.
XLV $164-$171
XBI $135-$144
UNH $365-$385
07
The Intelligence Take
What the market is missing
Analyst assessment
Treat Humana's Stars win and UnitedHealth's raise as real but priced, and don't confuse a rate-driven rotation into big pharma and payers with a fundamental all-clear; cost trend, the Fed and 340B still decide 2027.
01Stars, not earnings, reset MA economics this week. Humana's jump from 20% to 95% of members in 4+ star plans is worth billions in 2028 quality bonuses, and it arrives as AEP opens Oct 15 with average MA premiums falling to $12. The open question is how much of that windfall Humana spends on richer benefits to win share back from UnitedHealth and CVS, both of which are likely to see their 4+ star share fall.
02UnitedHealth's beat was real but flattered. Strip out the $610M reserve release and the medical care ratio was roughly 89.1%, still better than a year ago, but commercial trend above 11% and a guided 'low end' for 2027 growth tell you the cost cycle is not over. Employers and ACA buyers are the ones absorbing it: 15% median proposed exchange hikes follow 20% in 2026, Cigna is out of the exchanges for 2027 and enrollment is drifting toward an older, sicker pool.
03The market's message on Oct 14 was rotation, not fundamentals. Health care rallied on a hot CPI day while the 10-year rose, which is the opposite of how rate-sensitive pharma usually trades. That bid favors large-cap, cash-generating names (UNH, LLY, MRK, PFE) and leaves small biotech behind: XBI was flat and is down 2.3% for the week. We got this wrong last week, too. Our bear case expected a hot CPI to hit payers and biotech together, and payers rallied instead.
08
Confirmed Facts
What we know with high confidence
- ✓About 71% of MA drug-plan enrollees are in 4+ star contracts for 2027; average rating 3.99 vs 4.01 (Fierce Healthcare).
- ✓Humana: 95% of MA members in 4+ star plans for 2027 vs 20%; stock +11.6% on Oct 9 (Reuters; Robinhood).
- ✓UnitedHealth Q3: revenue $112.7B, adj EPS $4.69, MCR 88.4% incl. $610M reserve release; 2026 adj EPS guidance at least $20.50.
- ✓September CPI rose 3.7% y/y with core +0.3% m/m; S&P 500 health care rose 2.44% Oct 14 (TheStreet).
- ✓AHA, Maine Hospital Association and four safety-net hospitals filed a second suit in Maine federal court against the revamped 340B rebate pilot (Healthcare Dive).
09
Risks & Watch
What could break the thesis
- !Fed: core CPI at +0.3% raises the odds of a second hike at the Oct 27-28 FOMC, which would test whether the defensive rotation into pharma holds.
- !Elevance (Oct 21) and Molina (Oct 21) results: Medicaid and ACA cost trend will show whether UnitedHealth's 'stabilizing but elevated' read is industry-wide.
- !340B: a Maine court ruling on a preliminary injunction before the January start would decide whether safety-net hospitals must front drug costs in 2027.
- !Vykat XR: any FDA label or safety communication would hit Neurocrine's main growth asset; so far causality is undetermined.
10
Key Dates & Catalysts
The calendar ahead
11
Regulatory Landscape
CMS, FDA, and legislative status
FDA
FDA Status
October's PDUFA calendar is light; Daiichi Sankyo and Merck withdrew the I-DXd BLA for small cell lung cancer (Oct 10 date no longer pending). Next: GSK/Ionis bepirovirsen Oct 26, Summit ivonescimab Nov 14, Capricor deramiocel Nov 22. Vykat XR (Neurocrine) faces renewed safety scrutiny with 7 deaths and 100+ serious events in FAERS, causality undetermined.
CMS
CMS Status
2027 Star Ratings released: about 71% of MA drug-plan enrollees in 4+ star plans, average 3.99. Medicare open enrollment runs Oct 15 to Dec 7 with average MA premiums projected at $12.00 (from $14.37) and 34M MA enrollees. HRSA's revamped 340B rebate pilot starts in January; HRSA estimates $537M in annual costs, which hospitals say exceeds $1B.
LEG
Legislative Status
No major federal healthcare bill moved this week. A bipartisan bill to recruit rural health workers was introduced; an Axios-Ipsos poll found Medicare for All supporters outnumber opponents nearly 2 to 1 ahead of the midterms. Enhanced ACA tax credits remain expired, driving 2027 premium increases.
◆
Sources
All 28 sources
⌕
Showing 12 of 28
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28]